A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia

Clinical Therapeutics

Volumn 27, Issue 10, 2005, Pages 1612-1618

  Battaglia, John ^a   Houston, John P ^b   Ahl, Jonna ^b   Meyers, Adam L ^b   Kaiser, Christopher J ^b  

^a Program of Assertive Community Treatment   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Acute agitation; Intramuscular olanzapine; Oral transition dose; Schizophrenia

Indexed keywords

BENZODIAZEPINE; HALOPERIDOL; LORAZEPAM; OLANZAPINE; PLACEBO;

ADULT; AGITATION; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HOSPITAL; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HALOPERIDOL; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; PSYCHOMOTOR AGITATION; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS;

EID: 28444471164     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.10.001     Document Type: Article

References (17)

1. Currier G.W., and Trenton A. Pharmacological treatment of psychotic agitation CNS Drugs 16 2002 219 228
2. Allen M.H., Currier G.W., and Hughes D.H. Treatment of behavioral emergencies: A summary of the expert concensus guidelines J Psychiatr Pract 9 2003 16 38
3. Tandon R., and Jibson M.D. Extrapyramidal side effects of antipsychotic treatment: Scope of the problem and impact on outcome Ann Clin Psychiatry 14 2002 123 129
4. Jann M.W., and Bunt R.M. Switching antipsychotics drugs: A pharmacokinetic, pharmacodynamic, and practical perspective Psychopharmacol Bull 36 2002 22 41
5. Daniel D.G., Potkin S.G., and Reeves K.R. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial Psychopharmacology (Berl) 155 2001 128 134
6. Wright P., Birkett M., and David S.R. Double-blind, placebocontrolled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation inschizophrenia Am J Psychiatry 158 2001 1149 1151
7. Zimbroff D.L. Management of acute psychosis: From emergency to stabilization CNS Spectr 8 Suppl 2 2003 10 15
8. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr Bull 13 1987 261 276
9. Wright P., Meehan K., and Birkett M. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy Clin Ther 25 2003 1420 1428
10. text revision American Psychiatric Association, Task Force on DSM-IV Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 4th ed 2000 American Psychiatric Association Washington, DC
11. Olanzapine [package insert] 2003 Eli Lilly and Company Indianapolis, IN
12. Haloperidol [package insert] 1998 McNeil Pharmaceutical Spring House, Pa
13. Baker R.W., Kinon B.J., and Maguire G.A. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation J Clin Psychopharmacol 23 2003 342 348
14. Kinon B.J., Ahl J., Rotelli M.D., and McMullen E. Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia Am J Emerg Med 22 2004 181 186
15. Citrome L., and Volavka J. Optimal dosing of atypical antipsychotics in adults: A review of the current evidence Harv Rev Psychiatry 10 2002 280 291
16. Kinon B.J., Ahl J., and Stauffer V.J. Dose response and atypical antipsychotics in schizophrenia CNS Drugs 18 2004 597 616
17. Lipkovich I., Baron D., and Houston J. Flexible-dose clinical trials: Predictors and outcomes of antipsy chotic dose adjustments J Clin Psychopharmacol 25 2005 381 386